Skip to main content
Fig. 2 | Cancer & Metabolism

Fig. 2

From: An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells

Fig. 2

Analysis of DFO-resistant HeLa cells. A Evaluation of the degree of resistance of DFO-resistant cell lines. The statistical differences are indicated by **< 0.01 (Student’s t-test). B Principal component analysis-normalized metabolic data. Percentage values indicated on the axes represent the contribution rate of the first (PC1) and second (PC2) principal components to the total amount of variation. Cells were collected on 2 days after DFO treatment and analyzed. C Heat map of the hierarchical cluster analysis. The rows show the normalized levels of each metabolite. The dendrogram for each heatmap shows the relatedness of the normalized metabolite level patterns. D Pathway ranking by IPA. Reciprocal display of p-value calculated using the IPA software; magenta line is the ratio of metabolites included in each pathway

Back to article page